sequencing-based diagnostics
Congenica, Gabriel Precision Oncology Partner on Clinical Interpretation for Somatic Cancer Testing
University of Glasgow spinout Gabriel Precision Oncology will contribute a bioinformatics pipeline derived from cancer tissue samples to accelerate MDx adoption.
Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Adaptive Biotechnologies, GlaxoSmithKline Collaborate on MRD Testing
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
Illumina, Genomic Medicine Sweden to Evaluate Sequencing-Based Leukemia Diagnostics
The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.